NEW YORK (GenomeWeb News) – Axela Biosensors and Abnova of Taiwan today said they plan to co-develop reagents and biomarker panels to be used on Axela's dotLab system.
According to the companies, the dotLab system is a real-time protein-detection technology that can accelerate the analysis, validation, and commercialization of protein biomarkers.
Specifically, Abnova said it will optimize a series of monoclonal antibodies for the quantitation of specific serum protein biomarkers for use with Axela’s dotLab sensors.
Researchers will then be able to combine these monoclonal antibodies with their own reagents to create custom panels for multiplexed biomarker detection.
Financial terms of the deal were not disclosed.